BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company founded in 1997. It develops category-defining medicines that address the root cause of genetic conditions through genetic discovery. The company operates in more than 70 countries and employs approximately 3,000 people, working across the biotechnology, biopharmaceutical, pharmaceutical and genetic medicine sectors.

Its portfolio comprises nine approved therapies for rare genetic conditions, spanning enzyme replacement therapies and gene therapy. Alongside these, BioMarin maintains a pipeline of clinical and preclinical programs intended to produce further medicines for people living with rare genetic disorders. The company's technical work covers genetics, molecular biology, gene therapy, enzyme replacement therapy, rare disease drug development, and clinical and preclinical pipeline development.

The workforce includes scientists, researchers, engineers and support staff. BioMarin describes its culture as rooted in collaboration and purpose, with teams empowered to pursue genetic discoveries and a stated commitment to offering hope to patients with few or no prior treatment options.